Literature DB >> 883354

[Epidermiology and associated risk factors of hyperlipoproteinemia].

H Haller.   

Abstract

With the world-wide increase of the number of ischemic heart diseases the significance of the so-called factors of risk which initiate an arteriosclerosis or can deteriorate it, respectively, has increased. In the Dresden study concerning the most important factors of risk we found the following frequencies: obesity 8.2%, hyperlipoproteinemia 7.4%, hyperuricemia 3.8%, diabetes mellitus 2.0%, hypertension 17.2% and smoking 30.3%. From the investigations results the great significance of the combination of factors of risk which has a potentiating effect. The hyperlipoproteinemias of type III-V most frequently show a disturbed carbohydrate tolerance and hypertension. In them also the most frequent severe changes of the ECG appear. Myocardial infarctions concerned above all type II-IV. Apparantly concerning the vascular system patients with the combination hyperlipoproteinemia and carbohydrate metabolism are particularly endangered. The "metabolic syndrome" (obesity, diabetes mellitus, hyperlipoproteinemia, hyperuricemia, steatosis hepatis) with the increase of the viscosity of blood and plasma as well as disturbances of coagulation together with other factors of risk further the development of arteriosclerosis or has a directing influence on it. Nevertheless, the concept of the significance of the factors of risk is not able to predict the risk in every case. With the help of the apoproteins the metabolic risk is to be more exactly estimated by the determination of the lipid values in the individual classes of lipids or by classification.

Entities:  

Mesh:

Year:  1977        PMID: 883354

Source DB:  PubMed          Journal:  Z Gesamte Inn Med        ISSN: 0044-2542


  28 in total

1.  [History and definition(s) of metabolic syndrome].

Authors:  M Hanefeld; F Schaper; A Ceriello
Journal:  Internist (Berl)       Date:  2007-02       Impact factor: 0.743

2.  Is there an estrogenic component in the metabolic syndrome?

Authors:  S Starcke; G Vollmer
Journal:  Genes Nutr       Date:  2006-09       Impact factor: 5.523

Review 3.  Cardiovascular, renal and overall health outcomes after bariatric surgery.

Authors:  Ji C Tham; Carel W le Roux; Neil G Docherty
Journal:  Curr Cardiol Rep       Date:  2015-05       Impact factor: 2.931

Review 4.  Role of Hyperinsulinemia and Insulin Resistance in Hypertension: Metabolic Syndrome Revisited.

Authors:  Alexandre A da Silva; Jussara M do Carmo; Xuan Li; Zhen Wang; Alan J Mouton; John E Hall
Journal:  Can J Cardiol       Date:  2020-02-12       Impact factor: 5.223

5.  The awareness and prevalence of metabolic syndrome in medical community of bahawalpur.

Authors:  Mazhar Faiz Alam; Saima Nasreen; Ehsan Ullah; Anila Hussain
Journal:  Oman Med J       Date:  2011-01

Review 6.  The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  R Kahn; J Buse; E Ferrannini; M Stern
Journal:  Diabetologia       Date:  2005-09       Impact factor: 10.122

Review 7.  Metabolic consequences of sleep-disordered breathing.

Authors:  Jonathan Jun; Vsevolod Y Polotsky
Journal:  ILAR J       Date:  2009

Review 8.  Molecular Mechanisms of Sodium-Sensitive Hypertension in the Metabolic Syndrome.

Authors:  Jonathan M Nizar; Vivek Bhalla
Journal:  Curr Hypertens Rep       Date:  2017-08       Impact factor: 5.369

Review 9.  Hypothesis: could excessive fructose intake and uric acid cause type 2 diabetes?

Authors:  Richard J Johnson; Santos E Perez-Pozo; Yuri Y Sautin; Jacek Manitius; Laura Gabriela Sanchez-Lozada; Daniel I Feig; Mohamed Shafiu; Mark Segal; Richard J Glassock; Michiko Shimada; Carlos Roncal; Takahiko Nakagawa
Journal:  Endocr Rev       Date:  2009-01-16       Impact factor: 19.871

Review 10.  Care of the cancer survivor: metabolic syndrome after hormone-modifying therapy.

Authors:  Amanda J Redig; Hidayatullah G Munshi
Journal:  Am J Med       Date:  2010-01       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.